Product image of Levemir Innolet (Insulin Detemir) supplied by GNH India

Levemir Innolet

Active Ingredient:
Insulin Detemir
Origin:
EU

Levemir Innolet (Insulin Detemir)

Insulin detemir, the active ingredient in Levemir Innolet, is an insulin analog presented as a clear solution for subcutaneous use. It provides basal insulin coverage to help lower blood glucose levels in patients with diabetes mellitus, both type 1 and type 2.

GNH India supplies Levemir Innolet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable cold‑chain logistics for injectable products. Our network ensures timely delivery across EU and global markets.

Manufacturer / TM Owner

Novo Nordisk A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Levemir Innolet, an insulin analog, provides basal insulin support for diabetes management.
  • Type 1 diabetes mellitus: supplies long‑acting basal insulin to maintain fasting glucose control.
  • Type 2 diabetes mellitus: adds basal insulin when oral agents are insufficient to achieve glycemic targets.
  • Diabetes mellitus requiring basal insulin supplementation: delivers consistent insulin levels to reduce overall hyperglycemia.

How It Works

  • Insulin detemir binds to insulin receptors on peripheral tissues, activating the receptor tyrosine kinase pathway. This promotes translocation of GLUT‑4 transporters, enhancing glucose uptake into muscle and adipose cells, while suppressing hepatic glucose production. Its fatty‑acid side chain prolongs albumin binding, resulting in a prolonged, peak‑less basal insulin profile that lowers circulating glucose over 24 hours.

Side Effects

Levemir Innolet may be associated with several adverse reactions.

Common Side Effects

  • Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive.
  • Injection‑site reactions: redness, swelling, or itching at the injection site.
  • Weight gain: modest increase in body weight with chronic use.
  • Lipodystrophy: localized changes in subcutaneous fat.
  • Edema: mild fluid retention, often peripheral.
  • Headache: transient mild headaches.

Serious or Rare Side Effects

  • Severe hypoglycemia requiring assistance.
  • Anaphylactic or severe allergic reactions, including rash and angioedema.
  • Development of insulin antibodies that may alter glucose control.
  • Hypokalemia: low potassium levels in rare cases.
  • Necrotizing fasciitis at injection site (extremely rare).
  • Acute pancreatitis reported in isolated cases.

Precautions & Warnings

  • Before initiating therapy, consider the following precautions.
  • Monitor blood glucose regularly: adjust dose based on fasting and pre‑meal readings.
  • Renal impairment: reduce dose and monitor for hypoglycemia.
  • Hepatic disease: use with caution; liver dysfunction may affect insulin clearance.
  • Hypoglycemia unawareness: educate patients to recognize early symptoms.
  • Pregnancy and breastfeeding: only use if benefits outweigh potential risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levemir Innolet can interact with several medications.

Major Interactions (Avoid)

  • Concomitant sulfonylureas or meglitinides: may cause severe hypoglycemia.
  • Beta‑blockers: can mask hypoglycemia symptoms, making detection difficult.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors or ARBs: may potentiate insulin’s glucose‑lowering effect.
  • Thiazide diuretics: can increase blood glucose, requiring dose adjustment.
  • Corticosteroids: raise glucose levels, possibly necessitating higher insulin doses.
  • Oral contraceptives: may alter insulin requirements.
  • Alcohol: can precipitate delayed hypoglycemia, especially with missed meals.

Frequently Asked Questions

Levemir Innolet is a long‑acting insulin analog used to provide basal insulin coverage in adults with type 1 or type 2 diabetes mellitus. It helps maintain stable fasting and between‑meal blood glucose levels when oral agents or lifestyle changes are insufficient.

Insulin detemir binds to insulin receptors on muscle, fat, and liver cells, activating intracellular pathways that increase glucose uptake and reduce hepatic glucose production. Its fatty‑acid side chain prolongs albumin binding, creating a steady, peak‑less insulin level that lasts up to 24 hours.

The dose of Levemir Innolet is individualized by the prescribing healthcare professional based on the patient’s current glycemic control, body weight, renal function, and other medications. The prescriber determines the starting dose and any subsequent titration.

Safety data in pregnancy and lactation are limited. Levemir Innolet should only be used during pregnancy or while breastfeeding if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the Levemir Innolet product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

Levemir Innolet (insulin detemir) offers a relatively flat, peak‑less profile with a duration of up to 24 hours, similar to insulin glargine but with a slightly shorter action in some patients. It is less likely to cause weight gain than some alternatives and requires refrigeration, which may affect logistics compared with room‑temperature formulations.

Levemir Innolet must be stored in a refrigerator at 2‑8 °C. Keep the vial in its original carton, protect it from light, and avoid freezing. Once in use, the vial can be kept at controlled room temperature (up to 30 °C) for up to 28 days, but do not shake the solution.

Levemir Innolet is administered by subcutaneous injection, typically once daily at the same time each day. Injection sites include the abdomen, thigh, or upper arm, rotating sites to reduce lipodystrophy. The exact dosing schedule and injection technique should be instructed by a qualified healthcare professional.

The most serious risks are severe hypoglycemia, which can lead to loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of low blood sugar and to seek immediate medical attention if a severe reaction occurs.

Levemir Innolet should not be used by individuals with known hypersensitivity to insulin detemir or any of the excipients. It is also contraindicated in patients with severe hypoglycemia unawareness who cannot reliably monitor glucose levels, and in those for whom a rapid‑acting insulin is required instead of basal coverage.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Detemir

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT